Virtual Target Screening: Validation Using Kinase Inhibitors
暂无分享,去创建一个
Yuri Pevzner | H. Lee Woodcock | Daniel N. Santiago | Ashley A. Durand | Minh Phuong Tran | Rachel R. Scheerer | Kenyon G. Daniel | Shen-Shu Sung | Wayne C. Guida | Wesley H. Brooks | W. Guida | K. Daniel | H. Woodcock | S. Sung | W. Brooks | Yuri Pevzner | A. Durand | M. Tran
[1] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[2] J. Zheng,et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.
[3] Adrian H Elcock,et al. Progress toward virtual screening for drug side effects , 2002, Proteins.
[4] F. Almeida,et al. Implications of protein conformational diversity for binding and development of new biological active compounds. , 2006, Current medicinal chemistry.
[5] Y.Z. Chen,et al. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.
[6] Miklos Feher,et al. Consensus scoring for protein-ligand interactions. , 2006, Drug discovery today.
[7] G. Klebe,et al. Statistical potentials and scoring functions applied to protein-ligand binding. , 2001, Current opinion in structural biology.
[8] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[9] M. Milik,et al. Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.
[10] Yoshihiro Yamanishi,et al. Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..
[11] Bryan L. Roth,et al. Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.
[12] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[13] Robert P. Sheridan,et al. Multiple protein structures and multiple ligands: effects on the apparent goodness of virtual screening results , 2008, J. Comput. Aided Mol. Des..
[14] Adrian H Elcock,et al. Structure selection for protein kinase docking and virtual screening: homology models or crystal structures? , 2006, Current protein & peptide science.
[15] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[16] Sean Ekins,et al. The importance of discerning shape in molecular pharmacology. , 2009, Trends in pharmacological sciences.
[17] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[18] Bernard R. Brooks,et al. CHARMMing: A New, Flexible Web Portal for CHARMM , 2008, J. Chem. Inf. Model..
[19] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[20] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[21] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[22] W. L. Jorgensen,et al. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.
[23] C. Lyle,et al. Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity , 2004, Journal of Biological Chemistry.
[24] T. Halgren. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .
[25] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..
[26] J. Kuriyan,et al. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.
[27] Michael Karpusas,et al. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. , 2010, Biochemistry.
[28] Sai Lakshmana Vankayala,et al. Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. , 2008, Journal of medicinal chemistry.
[29] Sui Yung Chan,et al. Monitoring drug-protein interaction. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[30] G. Vigers,et al. Multiple active site corrections for docking and virtual screening. , 2004, Journal of medicinal chemistry.
[31] B. Chauffert,et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib , 2012, International journal of cancer.
[32] Francesco L Gervasio,et al. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. , 2012, Journal of the American Chemical Society.
[33] L. Meijer,et al. Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.
[34] G. Chang,et al. Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .
[35] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[36] Maria I. Zavodszky,et al. Scoring confidence index: statistical evaluation of ligand binding mode predictions , 2009, J. Comput. Aided Mol. Des..
[37] R. Hartmann,et al. Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. , 2007, Journal of medicinal chemistry.
[38] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[39] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[40] Alexander D. MacKerell,et al. Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation , 2009, PLoS Comput. Biol..
[41] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[42] E. Goldsmith,et al. Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.
[43] R. Margolis,et al. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition , 2010, Oncogene.
[44] Stephen K Burley,et al. A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[45] Steven J. M. Jones,et al. A Computational Approach to Finding Novel Targets for Existing Drugs , 2011, PLoS Comput. Biol..
[46] Y. Z. Chen,et al. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.
[47] Aurélien Grosdidier,et al. Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.
[48] Didier Rognan,et al. Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..
[49] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[50] Thomas A. Halgren,et al. Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..
[51] Thomas A. Halgren,et al. Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996 .
[52] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[53] Daniel Rauh,et al. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. , 2009, Journal of the American Chemical Society.
[54] J. Willem M. Nissink,et al. Simple Size-Independent Measure of Ligand Efficiency , 2009, J. Chem. Inf. Model..
[55] S. Holbeck,et al. Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.
[56] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[57] Claudio N. Cavasotto,et al. Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.
[58] W A Hendrickson,et al. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three‐dimensional structure. , 1990, The EMBO journal.
[59] Jérôme Hert,et al. Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..
[60] M. Boguski,et al. Repurposing with a Difference , 2009, Science.
[61] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[62] Thomas Lengauer,et al. Improved cyclodextrin-based receptors for camptothecin by inverse virtual screening. , 2007, Chemistry.
[63] T. Halgren,et al. Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .
[64] Yi Wang,et al. DITOP: drug-induced toxicity related protein database , 2007, Bioinform..
[65] Mathias Dunkel,et al. SuperDrug: a conformational drug database , 2005, Bioinform..
[66] Sean Ekins,et al. Reengineering the pharmaceutical industry by crash-testing molecules. , 2005, Drug discovery today.